Sivakesava Sakhamuri, Chief Technical Officer of CRISPR Therapeutics AG, filed a Form 4 on November 6, 2026, disclosing the acquisition of stock options covering 90,000 common shares and a restricted stock unit award covering 40,000 common shares, both granted on November 4, 2026.

Key Highlights

  • Stock option grant: Sakhamuri acquired options to purchase 90,000 Common Shares of CRISPR Therapeutics AG at an exercise price of $51.78, granted November 4, 2026, with an expiration date of November 4, 2036.
  • RSU grant: Sakhamuri also acquired 40,000 Restricted Stock Units on November 4, 2026, each representing a contingent right to receive one Common Share.
  • Option vesting schedule: 25% of the option shares vest on November 2, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter.
  • RSU vesting schedule: The 40,000 RSUs vest in four equal annual installments: one quarter each on November 2, 2027, November 2, 2028, November 2, 2029, and November 2, 2030.
  • Price of derivative securities: Both the stock option and RSU awards were acquired at a price of $0, according to the filing.
  • Post-transaction holdings: Following the reported transactions, Sakhamuri directly holds 90,000 stock options and 40,000 RSUs, as reported in the filing.

Sakhamuri's November 4, 2026 Equity Awards at CRISPR Therapeutics

According to the Form 4 filed with the U.S. Securities and Exchange Commission, Sivakesava Sakhamuri, serving as Chief Technical Officer of CRISPR Therapeutics AG (NASDAQ:CRSP), reported two derivative security acquisitions. Both transactions carried a transaction code of "A," indicating acquisition, and both are listed as directly owned. The filing was signed by Elizabeth Ryland Waldinger as attorney-in-fact on November 6, 2026.

The first award is a stock option granting Sakhamuri the right to purchase 90,000 Common Shares at an exercise price of $51.78. Per the filing's explanation of responses, 25% of the shares subject to the option shall vest on November 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter. The option expires on November 4, 2036.

The second award consists of 40,000 Restricted Stock Units, each of which the filing describes as "a contingent right to receive one share of CRSP Common Shares." The RSUs vest in four equal annual installments, with one quarter vesting on each of November 2, 2027, November 2, 2028, November 2, 2029, and November 2, 2030. The filing does not indicate any activity in Table I (non-derivative securities) in connection with these grants.

What Was Disclosed

Sivakesava Sakhamuri, Chief Technical Officer of CRISPR Therapeutics AG, disclosed the grant of stock options covering 90,000 shares at $51.78 and 40,000 RSUs on November 4, 2026, with multi-year vesting schedules, in a Form 4 filed November 6, 2026.